step 7 semaglutide Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Once-weekly semaglutide 7·2 mg in

Joint degeneration can negatively impact your quality of life by limiting your movement and mobility

doi: 10.1159/000046880

However, diabetic patients taking GLP-1 drugs may face increased risks for both conditions

Our proposal focuses on removing activities that do not lead to demonstrable improvements in patient outcomes, rather than those that address specific population needs through evidence-based clinical intervention

We spoke with obesity medicine specialist and Calibrate Clinical Director Kristin Baier, MD, about what to know

The best that can be done is a rough estimation of the BAC level based on known inputs